{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:53:25Z","timestamp":1790621605316,"version":"4.1.0"},"reference-count":239,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Belluck and Fox"},{"name":"The EDRN Mesothelioma Biomarker Discovery Laboratory","award":["5U01CA214195-04"],"award-info":[{"award-number":["5U01CA214195-04"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UH Foundation"},{"name":"Honeywell International Inc"},{"name":"Riviera United-4-a Cure"},{"name":"Maurice and Joanna Sullivan Family Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.thorsurg.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T09:12:26Z","timestamp":1600074746000},"page":"395-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mesothelioma Biomarkers"],"prefix":"10.1016","volume":"30","author":[{"given":"Harvey I.","family":"Pass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Alimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra M.","family":"Goparaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thorsurg.2020.08.001_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/occmed\/kqn086","article-title":"Asbestos-related diseases: time for technology sharing","volume":"58","author":"Takahashi","year":"2008","journal-title":"Occup Med (Lond)"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib5","first-page":"875","article-title":"Simian virus 40: the link with human malignant mesothelioma is well established","volume":"20","author":"Carbone","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J","article-title":"Simian virus 40 and human tumors: it is time to study mechanisms","volume":"76","author":"Carbone","year":"1999","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib7","doi-asserted-by":"crossref","first-page":"14128","DOI":"10.1073\/pnas.0604544103","article-title":"Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters","volume":"103","author":"Kroczynska","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib11","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib13","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib16","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib17","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/JTO.0b013e318211127a","article-title":"Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma","volume":"6","author":"Kadota","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib23","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib24","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib25","doi-asserted-by":"crossref","first-page":"102815","DOI":"10.1016\/j.critrevonc.2019.102815","article-title":"Emerging therapies in malignant pleural mesothelioma","volume":"144","author":"Cinausero","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib26","first-page":"82","article-title":"Surgical controversies in mesothelioma: MesoVATS addresses the role of surgical debulking","volume":"5","author":"Hoang","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00066-016-1092-7","article-title":"Role of postoperative radiotherapy in the management of malignant pleural mesothelioma: a propensity score matching of the SEER database","volume":"193","author":"Abdel-Rahman","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib28","first-page":"Cd012605","article-title":"Radical multimodality therapy for malignant pleural mesothelioma","volume":"1","author":"Abdel-Rahman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fonc.2019.00740","article-title":"Liquid biopsy in malignant pleural mesothelioma: state of the art, pitfalls, and perspectives","volume":"9","author":"Cavallari","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/cancers11060831","article-title":"Breath analysis: a systematic review of volatile organic compounds (VOCs) in diagnostic and therapeutic management of pleural mesothelioma","volume":"11","author":"Catino","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib32","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2019.06.020","article-title":"Pathologic considerations and standardization in mesothelioma clinical trials","volume":"14","author":"Tsao","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib35","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib38","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib39","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"Ho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib41","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-07-0607","article-title":"Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study","volume":"17","author":"Amati","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib45","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Rodriguez Portal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.rmed.2009.05.017","article-title":"Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis","volume":"104","author":"Luo","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib49","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12032-012-0422-6","article-title":"Individual predictors of increased serum mesothelin in asbestos-exposed workers","volume":"30","author":"Filiberti","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib51","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200802-258OC","article-title":"Soluble mesothelin-related protein in an asbestos-exposed population: the Dust Diseases Board cohort study","volume":"178","author":"Park","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib52","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.athoracsur.2008.03.016","article-title":"A\u00a0phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results","volume":"86","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib54","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.athoracsur.2017.06.042","article-title":"Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma","volume":"104","author":"Burt","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/JTO.0b013e31820db377","article-title":"Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib56","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib57","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib58","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A\u00a0serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Linch","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib60","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib61","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib62","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib64","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12885-018-4113-3","article-title":"A\u00a0prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma","volume":"18","author":"de Fonseka","year":"2018","journal-title":"BMC cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib66","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib67","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1349-7006.2006.00246.x","article-title":"Novel ELISA system for detection of N-ERC\/mesothelin in the sera of mesothelioma patients","volume":"97","author":"Shiomi","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib68","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib69","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib70","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1515\/CCLM.2010.165","article-title":"Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population","volume":"48","author":"Park","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib71","first-page":"1427","article-title":"Impact of renal failure on the tumor markers of mesothelioma, N-ERC\/mesothelin and osteopontin","volume":"31","author":"Shiomi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jss.2004.03.028","article-title":"The role of osteopontin in tumor metastasis","volume":"121","author":"Wai","year":"2004","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib73","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s11033-010-0481-8","article-title":"Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression","volume":"38","author":"Chen","year":"2011","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib74","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/onc.2009.478","article-title":"Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells","volume":"29","author":"Tajima","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib75","first-page":"2205","article-title":"Osteopontin modulates malignant pleural mesothelioma cell functions in\u00a0vitro","volume":"29","author":"Ohashi","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib76","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2559.2007.02675.x","article-title":"Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma","volume":"50","author":"Frey","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-1405-2","article-title":"Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies","volume":"10","author":"Coppola","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib78","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12885-016-2541-5","article-title":"Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer","volume":"16","author":"Rouanne","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib79","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1349-7006.2010.01561.x","article-title":"Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells","volume":"101","author":"El-Tanani","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib80","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib81","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2009.03.042","article-title":"Tumorigenic properties of alternative osteopontin isoforms in mesothelioma","volume":"382","author":"Ivanov","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00420-013-0853-1","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib83","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/carcin\/21.5.1023","article-title":"mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats","volume":"21","author":"Sandhu","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib84","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib85","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Cristaudo","year":"2010","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/CCLM.2010.066","article-title":"Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels","volume":"48","author":"Rai","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib87","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460080902400208","article-title":"Osteopontin is not a specific marker in malignant pleural mesothelioma","volume":"24","author":"Paleari","year":"2009","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2011.02.007","article-title":"Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma\u2014which is best?","volume":"74","author":"Creaney","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib90","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","article-title":"Prognostic role of osteopontin expression in malignant pleural mesothelioma","volume":"130","author":"Cappia","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib91","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jtho.2016.02.006","article-title":"Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma","volume":"11","author":"Pass","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib92","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","article-title":"Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study","volume":"44","author":"Bruno","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib93","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.5301\/jbm.5000229","article-title":"Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib94","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2012.06.019","article-title":"The dual role of fibulins in tumorigenesis","volume":"325","author":"Obaya","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib95","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.exer.2009.09.018","article-title":"Focus on molecules: fibulin-3 (EFEMP1)","volume":"90","author":"Zhang","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib96","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib97","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejcdt.2013.10.004","article-title":"Role of fibulin-3 in the diagnosis of malignant mesothelioma","volume":"63","author":"Agha","year":"2014","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure","volume":"194","author":"Demir","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib99","doi-asserted-by":"crossref","first-page":"1725354","DOI":"10.1155\/2017\/1725354","article-title":"Plasma fibulin-3 as a potential biomarker for patients with asbestos-related diseases in the han population","volume":"2017","author":"Jiang","year":"2017","journal-title":"Dis markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib100","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.7314\/APJCP.2015.16.4.1403","article-title":"Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma","volume":"16","author":"Kaya","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib101","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib102","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.21873\/anticanres.11460","article-title":"Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma","volume":"37","author":"Battolla","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib103","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.18632\/oncotarget.14712","article-title":"Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: evidence from a meta-analysis","volume":"8","author":"Pei","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib104","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-17-1628","article-title":"Development of a function-blocking antibody against fibulin-3 as a targeted reagent for glioblastoma","volume":"24","author":"Nandhu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrc.2016.153","article-title":"Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer","volume":"17","author":"Borrebaeck","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib106","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/prca.201300052","article-title":"Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins","volume":"8","author":"Giusti","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib107","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib108","doi-asserted-by":"crossref","first-page":"e26332","DOI":"10.1371\/journal.pone.0026332","article-title":"From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay","volume":"6","author":"Kraemer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib109","doi-asserted-by":"crossref","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jprot.2018.09.018","article-title":"Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma","volume":"192","author":"White","year":"2019","journal-title":"J\u00a0Proteomics"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib111","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1559-0275-10-16","article-title":"Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring","volume":"10","author":"Cerciello","year":"2013","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib112","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.thorsurg.2020.08.001_bib113","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib114","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib116","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-04-2181","article-title":"Validation of genomics-based prognostic tests in malignant pleural mesothelioma","volume":"11","author":"Gordon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib117","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djx175","article-title":"Quantitative Clinical staging for patients with malignant pleural mesothelioma","volume":"110","author":"Gill","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib118","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2019.00078","article-title":"Development and validation of a prognostic signature for malignant pleural mesothelioma","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic events associated with progression of pleural malignant mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib121","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib122","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib123","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"35","key":"10.1016\/j.thorsurg.2020.08.001_bib124","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A\u00a0subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12253-013-9677-2","article-title":"BAP1 protein is a progression factor in malignant pleural mesothelioma","volume":"20","author":"Arzt","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib126","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib127","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-008-0689-3","article-title":"Prognostic significance of p16\/cdkn2a loss in pleural malignant mesotheliomas","volume":"453","author":"Dacic","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"Chou","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Di Leva","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib131","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib132","first-page":"129","article-title":"miRBase: the microRNA sequence database","volume":"342","author":"Griffiths-Jones","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib133","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12935-015-0185-1","article-title":"MicroRNA (miRNA) in cancer","volume":"15","author":"Reddy","year":"2015","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib134","first-page":"1031","article-title":"MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib135","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/aps.2015.67","article-title":"Genome-wide analysis of microRNA and mRNA expression signatures in cancer","volume":"36","author":"Li","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib136","doi-asserted-by":"crossref","first-page":"e0135331","DOI":"10.1371\/journal.pone.0135331","article-title":"Two different serum MiRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients","volume":"10","author":"Lamberti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib137","doi-asserted-by":"crossref","first-page":"e114483","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib138","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib139","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications","volume":"42","author":"Busacca","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma\u2014a miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib141","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c\u2217 is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib142","doi-asserted-by":"crossref","first-page":"22809","DOI":"10.1074\/jbc.M110.100354","article-title":"Pro-tumorigenic effects of miR-31 loss in mesothelioma","volume":"285","author":"Ivanov","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib143","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clinbiochem.2012.02.009","article-title":"Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients","volume":"45","author":"Tomasetti","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib144","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib145","doi-asserted-by":"crossref","first-page":"58606","DOI":"10.18632\/oncotarget.9686","article-title":"Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis","volume":"7","author":"Micolucci","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib146","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review","volume":"8","author":"Lo Russo","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib147","doi-asserted-by":"crossref","first-page":"9645940","DOI":"10.1155\/2017\/9645940","article-title":"MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study","volume":"2017","author":"Mozzoni","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib148","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmoldx.2014.03.002","article-title":"Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma","volume":"16","author":"Andersen","year":"2014","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib149","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/bmm-2017-0224","article-title":"Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients","volume":"12","author":"Matboli","year":"2018","journal-title":"Biomark Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib150","unstructured":"Sun JG, Pass H. MicroRNAs for Diagnosis and Prognosis of Mesothelioma. In Poster Presentation Edition. San Diego, CA: AATS Annual Meeting, April 28 - May 1, 2018."},{"key":"10.1016\/j.thorsurg.2020.08.001_bib151","doi-asserted-by":"crossref","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib152","doi-asserted-by":"crossref","first-page":"e0176680","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib153","doi-asserted-by":"crossref","first-page":"e30221","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma\u2014a pilot study","volume":"7","author":"Weber","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib154","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2019","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12032-014-0303-2","article-title":"Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component","volume":"31","author":"Matsumoto","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib156","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib157","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib158","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"De Santi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib159","first-page":"6223","article-title":"Methylation-associated silencing of microRNA-126 and its host gene EGFL7 in malignant pleural mesothelioma","volume":"35","author":"Andersen","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated expression of the microRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib161","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00428-017-2133-z","article-title":"miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma","volume":"470","author":"Mairinger","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib162","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De Rubis","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib163","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib164","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","article-title":"Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients","volume":"124","author":"Hylebos","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib166","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.lungcan.2013.09.017","article-title":"The degree of microRNA-34b\/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma","volume":"82","author":"Muraoka","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib167","first-page":"2139","article-title":"Droplet digital PCR as a novel system for the detection of microRNA34b\/c methylation in circulating DNA in malignant pleural mesothelioma","volume":"54","author":"Sato","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib168","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib169","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2013.05.014","article-title":"The role of epigenetics in malignant pleural mesothelioma","volume":"81","author":"Vandermeers","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral blood DNA methylation as potential biomarker of malignant pleural mesothelioma in asbestos-exposed subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib171","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/crj.12573","article-title":"Circulating tumor cells as a potential biomarker in diagnosis of lung cancer: a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib172","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/CBM-140448","article-title":"Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma","volume":"15","author":"Raphael","year":"2015","journal-title":"Cancer Biomark"},{"issue":"Suppl 4","key":"10.1016\/j.thorsurg.2020.08.001_bib173","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1245\/s10434-013-3399-2","article-title":"Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM)","volume":"21","author":"Yoneda","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib174","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/or.2016.5235","article-title":"EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip","volume":"37","author":"Chikaishi","year":"2017","journal-title":"Oncol Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib176","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.2922595","article-title":"Specific recognition of cruciform DNA by nuclear protein HMG1","volume":"243","author":"Bianchi","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib177","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from cell death to new life","volume":"6","author":"Venereau","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib178","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.1316925111","article-title":"JAK\/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation","volume":"111","author":"Lu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib179","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbrc.2009.10.129","article-title":"The extracellular release of Schistosoma mansoni HMGB1 nuclear protein is mediated by acetylation","volume":"390","author":"Carneiro","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib180","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib181","first-page":"173","article-title":"Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite","volume":"25","author":"Wang","year":"2004","journal-title":"Int J Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib182","doi-asserted-by":"crossref","first-page":"5756102","DOI":"10.1155\/2017\/5756102","article-title":"Serum HMGB1 as a potential biomarker for patients with asbestos-related diseases","volume":"2017","author":"Ying","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib183","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib184","doi-asserted-by":"crossref","first-page":"50417","DOI":"10.18632\/oncotarget.10413","article-title":"HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib186","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib187","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib188","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib189","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","article-title":"Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board","volume":"14","author":"Kao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib190","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/bjc.2013.504","article-title":"Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma","volume":"109","author":"Meniawy","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib191","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12094-013-1146-6","article-title":"Expression of Wilms' tumor gene (WT1) is associated with survival in malignant pleural mesothelioma","volume":"16","author":"Cedr\u00e9s","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib192","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1038\/s41598-017-16551-7","article-title":"Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma","volume":"7","author":"Klikovits","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib193","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1083\/jcb.105.3.1343","article-title":"Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons","volume":"105","author":"Rogers","year":"1987","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib194","first-page":"4003","article-title":"Identification of calretinin and the alternatively spliced form calretinin-22k in primary pleural mesotheliomas and in their metastases","volume":"24","author":"Schwaller","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-10-242","article-title":"Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients","volume":"10","author":"Raiko","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib196","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib197","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7150\/ijms.23939","article-title":"Biomarkers for predicting malignant pleural mesothelioma in a Mexican population","volume":"15","author":"Aguilar-Madrid","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib198","doi-asserted-by":"crossref","first-page":"e017104","DOI":"10.1136\/bmjopen-2017-017104","article-title":"Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study","volume":"7","author":"Casjens","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib199","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin\u2014a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib200","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","article-title":"Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma","volume":"48","author":"Thapa","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib201","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/1071576031000083107","article-title":"Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases","volume":"37","author":"Morre","year":"2003","journal-title":"Free Radic Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12014-008-9016-x","article-title":"Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase","volume":"5","author":"Hostetler","year":"2009","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib203","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12014-016-9103-3","article-title":"ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4\u201310 years in advance of clinical symptoms","volume":"13","author":"Morr\u00e9","year":"2016","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib204","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.abb.2015.02.025","article-title":"The paradoxical role of thioredoxin on oxidative stress and aging","volume":"576","author":"Cunningham","year":"2015","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib206","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib207","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Hirayama","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib209","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib210","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A\u00a0phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib211","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib212","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/10409238.2013.770819","article-title":"Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade","volume":"48","author":"Vandooren","year":"2013","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib213","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2478\/raon-2018-0005","article-title":"Matrix metalloproteinases polymorphisms as baseline risk predictors in malignant pleural mesothelioma","volume":"52","author":"\u0160trbac","year":"2018","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib214","doi-asserted-by":"crossref","first-page":"8069529","DOI":"10.1155\/2017\/8069529","article-title":"Matrix metalloproteinases polymorphisms as prognostic biomarkers in malignant pleural mesothelioma","volume":"2017","author":"\u0160trbac","year":"2017","journal-title":"Dis markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib215","doi-asserted-by":"crossref","first-page":"1242964","DOI":"10.1155\/2019\/1242964","article-title":"Evaluation of matrix metalloproteinase 9 serum concentration as a biomarker in malignant mesothelioma","volume":"2019","author":"\u0160trbac","year":"2019","journal-title":"Dis markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib216","doi-asserted-by":"crossref","first-page":"e1000312","DOI":"10.1371\/journal.pbio.1000312","article-title":"BIN1 localizes the L-type calcium channel to cardiac T-tubules","volume":"8","author":"Hong","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib217","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.02.005","article-title":"High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes","volume":"130","author":"Ahmadzada","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib218","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jmb.2009.01.035","article-title":"The beta(E)-domain of wheat E(c)-1 metallothionein: a metal-binding domain with a distinctive structure","volume":"387","author":"Peroza","year":"2009","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib219","doi-asserted-by":"crossref","first-page":"22254","DOI":"10.18632\/oncotarget.24962","article-title":"Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy","volume":"9","author":"Mairinger","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib220","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bbagen.2013.09.033","article-title":"Human aquaporins: regulators of transcellular water flow","volume":"1840","author":"Day","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib221","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/ijms19030685","article-title":"Immunohistochemical expression of aquaporin-1 in fluoro-edenite-induced malignant mesothelioma: a preliminary report","volume":"19","author":"Angelico","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib222","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cyt.12583","article-title":"Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: an approach by cell-block procedure","volume":"29","author":"Angelico","year":"2018","journal-title":"Cytopathology"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib223","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib224","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11033-019-04715-9","article-title":"Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma","volume":"46","author":"Sobhani","year":"2019","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib227","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma","volume":"197","author":"Jimenez-Ramirez","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib228","doi-asserted-by":"crossref","first-page":"3510984","DOI":"10.1155\/2017\/3510984","article-title":"A\u00a0novel panel of serum biomarkers for MPM diagnosis","volume":"2017","author":"Bonotti","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib229","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cllc.2019.08.003","article-title":"Development of a novel prognostic risk classification system for malignant pleural mesothelioma","volume":"21","author":"Doi","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib230","doi-asserted-by":"crossref","first-page":"027108","DOI":"10.1088\/1752-7155\/6\/2\/027108","article-title":"The versatile use of exhaled volatile organic compounds in human health and disease","volume":"6","author":"Boots","year":"2012","journal-title":"J\u00a0Breath Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib231","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acsinfecdis.7b00088","article-title":"Exhaled volatile organic compounds of infection: a systematic review","volume":"3","author":"Ahmed","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib232","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1158\/1055-9965.EPI-13-0737","article-title":"Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma\u2014a hypothesis","volume":"23","author":"Lamote","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib233","doi-asserted-by":"crossref","first-page":"024001","DOI":"10.1088\/1752-7163\/aaa499","article-title":"The potential role of exhaled breath analysis in the diagnostic process of pneumonia\u2014a systematic review","volume":"12","author":"van Oort","year":"2018","journal-title":"J\u00a0Breath Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib234","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/tlcr.2018.04.09","article-title":"Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review","volume":"7","author":"Brusselmans","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib235","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00056-2019","article-title":"Exhaled volatile organic compounds in adult asthma: a systematic review","volume":"54","author":"Azim","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib236","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-anchem-071213-020043","article-title":"Analysis of exhaled breath for disease detection","volume":"7","author":"Amann","year":"2014","journal-title":"Annu Rev Anal Chem (Palo Alto Calif)"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib237","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1039\/c1an15082k","article-title":"Ambient analysis of trace compounds in gaseous media by SIFT-MS","volume":"136","author":"Smith","year":"2011","journal-title":"Analyst"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib238","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00919-2017","article-title":"Exhaled breath to screen for malignant pleural mesothelioma: a validation study","volume":"50","author":"Lamote","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.thorsurg.2020.08.001_bib239","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412720300633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412720300633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:34:09Z","timestamp":1761546849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412720300633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":239,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1547412720300633"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.001","relation":{},"ISSN":["1547-4127"],"issn-type":[{"value":"1547-4127","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelioma Biomarkers","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}